REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...
This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...
A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1...
Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...
